<DOC>
	<DOCNO>NCT01335256</DOCNO>
	<brief_summary>Clinical study determine safety , tolerability , maximum tolerate dose BAY1000394 give 4 week / 2 week schedule patient advance solid tumor</brief_summary>
	<brief_title>Clinical Study Evaluate Safety Maximum Tolerated Dose BAY1000394 Given 4 Week / 2 Week Off Schedule Subjects With Advanced Malignancies</brief_title>
	<detailed_description />
	<criteria>Life expectancy least 12 week Subjects advance , histologically cytologically confirm solid tumor , refractory standard therapy , standard therapy available , subject must actively refuse treatment would regard standard , / judgment investigator , experimental treatment clinically ethically acceptable At least 1 tumor lesion measurable computer tomography ( CT ) scan magnetic resonance imaging ( MRI ) accord RECIST 1.1 Estimated creatinine clearance 60 mL/min accord Modification Diet Renal Disease Study Group ( MDRD ) formula ( 2 ) Women childbearing potential must negative serum pregnancy test perform within 7 day prior first dose study drug Subjects history hypertension stable antihypertensive treatment 7 day prior first dose study drug Ability understand willingness sign write informed consent . A sign informed consent must obtain prior studyspecific procedure . Any patient potentially curable disease explicity exclude enrollment study Known hypersensitivity study drug ( active investigational medicinal product excipients preparation ) agent give association study History cardiac disease : congestive heart failure &gt; NYHA Class II , unstable angina ( anginal symptom rest ) , newonset angina ( within past 3 month prior study entry ) , myocardial infarction within past 3 month prior study entry , cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) Moderate severe hepatic impairment , i.e . ChildPugh class B C ( 3 ) History human immunodeficiency virus ( HIV ) infection chronic hepatitis B C Symptomatic metastatic brain meningeal tumor unless subject &gt; 3 month definitive therapy , evidence tumor growth image study within 4 week prior study entry , clinically stable respect tumor time study entry . Subjects must acute steroid therapy taper steroid therapy ( chronic steroid therapy acceptable provide dose stable 4 week prior study entry follow screen CT / MRI scan ) . Subjects neurological symptom undergo CT / MRI scan brain exclude new progressive brain metastasis . Spinal cord metastasis acceptable Previous coexist cancer distinct primary site histology cancer evaluate study EXCEPT cervical cancer insitu , treat basal cell carcinoma , superficial bladder tumor [ Ta Tis ] , cancer curatively treat &gt; 3 year prior study entry Anticancer chemotherapy immunotherapy within 4 week study entry . Mitomycin C nitrosoureas give within 6 week study entry . Anticancer therapy define agent combination agent clinically proven anti tumor activity administer route purpose affect malignancy , either directly indirectly , include palliative therapeutic endpoint . Accepted exception bisphosphonates , Luteinizing hormonereleasing hormone ( LHRH ) agonists prostate cancer , mitotane adrenal carcinoma . Radiotherapy target lesion within 3 week prior first dose study drug . Palliative radiotherapy allow described Section 6.9 protocol . Radiotherapy target lesion study regard progressive disease Use biological response modifier , granulocytecolony stimulate factor ( GCSF ) , within 3 week prior first dose study drug . Granulocytecolony stimulate factor ( GCSF ) hematopoietic growth factor may use management acute toxicity febrile neutropenia clinically indicate discretion investigator , however , may substitute require dose reduction</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Phase I , dose escalation , kinase inhibitor , cyclin-dependent kinase inhibitor , target therapy , small molecule</keyword>
</DOC>